. HIV attacks T-helper (CD4) cells, the white blood cells responsible for cell-mediated immunity, and interferes with the body's immune system and function. AIDS occurs when the immune system is severely weakened by HIV to the point that opportunistic infections or cancers can begin to develop (USDHHS, 2019) . To prevent potentially life-threatening complications, HIV treatment is initiated as soon as possible following diagnosis. According to the USDHHS (2018), combination antiretroviral therapy (cART), previously known as highly active antiretroviral therapy, is recommended over traditional monotherapy to prevent virologic failure and the development of drug resistance.
Despite becoming widespread in the mid-to late 1990s, initiation of cART is often delayed until CD4 cell counts drop to less than 200/mcL, at which point an individual is diagnosed with AIDS (USDHHS, 2019). Although treatment with cART reduces immunosuppression and significantly decreases cancer burden, many factors contribute to higher cancer risks for patients with virally suppressed immune systems. These factors include chronic inflammation and Patients with HIV who are diagnosed with cancer can face worse outcomes because of cancer care disparities, as well as a lack of appropriate cancer treatments available for this population. These disparities in care, which often occur regardless of comorbidities or insurance status, can lead to higher mortality when compared to patients with cancer who do not have HIV (Reid et al., 2018; Suneja et al., 2014 Suneja et al., , 2016 
